Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, Bafna Pharmaceuticals has informed that Palamadai Krishnan Sundaresan (DIN: 06954189) will be retiring as an Independent Director of the Company upon completion of his first term, with effect from close of business hours on June 24, 2025. Consequently, he will also cease to be the Chairman of the Audit Committee and a Member of the Nomination & Remuneration Committee of the Company. Further, it has informed that due to the change in composition of the Board of Directors, the Board of Directors has re-constituted the composition of the Committees with effect from June 25, 2025, as details enclosed. Notwithstanding the aforesaid retirement of the Independent Director, the composition of the Board and its Committees continues to remain in compliance with the requirements of the applicable laws. The disclosures as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are provided in Annexure - I.
The above information is a part of company’s filings submitted to BSE.
